Global, Multi-Program Collaboration Now Includes Anokion’s Novel Product Candidates for Celiac Disease, in addition to Multiple Sclerosis and the Platform CAMBRIDGE, Mass. & LAUSANNE, Switzerland--( BUSINESS WIRE )-- Anokion SA , a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced the expansion of an exclusive global collaboration agreement with Bristol Myers Squibb, focused
September 22, 2020
· 3 min read